Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Odd Erik Johansen"'
Autor:
Richard E. Pratley, Julio Rosenstock, Bernard Zinman, Mark A. Espeland, Yutaka Seino, Darren K. McGuire, Maria Weber, Odd Erik Johansen, Michaela Mattheus, Nikolaus Marx, Annett Keller, Knut Robert Andersen, Takashi Kadowaki
Publikováno v:
Diabetes, obesity and metabolism 23(2), 569-580 (2021). doi:10.1111/dom.14254
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism
Diabetes, obesity and metabolism 23(2), 569-580 (2021). doi:10.1111/dom.14254
Published by Wiley-Blackwell, Oxford [u.a.]
Published by Wiley-Blackwell, Oxford [u.a.]
Autor:
Stefan Kaspers, Stuart J. Pocock, Stefan D. Anker, Michaela Mattheus, Silvio E. Inzucchi, Søren S Lund, Maximilian von Eynatten, Christoph Wanner, Jyothis T. George, Waheed Jamal, Stefan Hantel, Bernard Zinman, Odd Erik Johansen, David Fitchett, Ulrich Elsasser, Darren K. McGuire
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:949-959
Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in t
Autor:
Isabella Zwiener, Naveed Sattar, Jyothis T. George, Prabhav Trivedi, Silvio E. Inzucchi, Kamlesh Khunti, Melanie J. Davies, Odd Erik Johansen
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To investigate the association of different categories of baseline cardio‐metabolic risk factors on the treatment effects of empagliflozin 10 and 25 mg when added as second‐line therapy to metformin in patients with type 2 diabetes (T2D). Mat
Autor:
Yutaka Seino, Christoph Wanner, Odd Erik Johansen, Douglas Clark, Mark E. Cooper, Julio Rosenstock, Sven Schnaidt, Takashi Kadowaki
Publikováno v:
Diabetes, Obesity & Metabolism
Aims In CARMELINA®, linagliptin demonstrated cardiovascular and renal safety in patients with type 2 diabetes (T2D) with high renal and cardiovascular disease (CVD) risk. We investigated safety and efficacy of this dipeptidyl peptidase‐4 inhibitor
Autor:
Ilkka Tikkanen, David Z.I. Cherney, Hans-Juergen Woerle, Søren S Lund, Egon Pfarr, Mark E. Cooper, Odd Erik Johansen, Uli C. Broedl
Publikováno v:
Kidney International. 93:231-244
Sodium glucose cotransporter 2 (SGLT2) inhibitors reduce HbA1c, blood pressure, and weight in patients with type 2 diabetes. To investigate the effect of renal function on reductions in these parameters with the SGLT2 inhibitor empagliflozin, we asse
Autor:
Jyothis T. George, Bernard Zinman, Michaela Mattheus, Christoph Wanner, Silvio E. Inzucchi, David Fitchett, Ola Vedin, Odd Erik Johansen
Publikováno v:
European Heart Journal
Aims Hypoglycaemia, in patients with Type 2 diabetes (T2D) is associated with an increased risk for cardiovascular (CV) events. In EMPA-REG OUTCOME, the sodium-glucose co-transporter-2 inhibitor empagliflozin reduced the risk of CV death by 38% and h
Autor:
Odd Erik Johansen, Bernard Zinman, Julio Rosenstock, Egon Pfarr, Darren K. McGuire, Mark A. Espeland, David Baanstra, Steven E. Kahn, Hans J. Woerle, Jyothis T. George, Nikolaus Marx, Thomas Meinicke, Annett Keller, Michaela Mattheus, Maximilian von Eynatten
Publikováno v:
JAMA. 322:1155
Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparato
Autor:
Uli C. Broedl, Hans-Juergen Woerle, Stefan Kaspers, Jens Eilbracht, Thomas R. Pieber, Odd Erik Johansen, Nima Soleymanlou, Jessica Cescutti, S. Famulla
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes. Methods A total of 75 patients with glycated haemoglobin (HbA1c) concentrations of ≥7.5 to ≤10.5% (≥58 to ≤
Autor:
Maximillian von Eynatten, John H. Alexander, Christoph Wanner, Steven E. Kahn, Robert D. Toto, Nikolaus Marx, Julio Rosenstock, Egon Pfarr, David Baanstra, Darren K. McGuire, Michael J. Pencina, Odd Erik Johansen, Jyothis T. George, Vlado Perkovic, HJ Woerle, Thomas Meinicke, Bernard Zinman, Sven Schnaidt, Mark E. Cooper
Publikováno v:
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 321(1), 69-79. AMER MEDICAL ASSOC
IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kid
Autor:
Dietmar Neubacher, Bernard Zinman, Sanjay Patel, Odd Erik Johansen, Hans-Juergen Woerle, Bo Ahrén
Publikováno v:
Canadian journal of diabetes. 40(1)
With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl pepti